T1	HMM 35 70	renal blood flow and renal function
T2	HMM 184 228	effects on the treatment of severe hepatitis
T3	HMM 317 345	complication of renal damage
T4	HMM 349 370	hepatorenal syndrome.
T5	HMM 449 554	plasma renin activity (PRA), angiotensin II (AII), aldosterone (ALD), renal blood flow and renal function
T6	HMM 929 950	Basic autohemotherapy
T7	HMM 1231 1232	.
T8	HMM 1233 1293	PRA, AII, ALD, renal blood flow and damage to renal function
T9	HMM 1370 1371	.
T10	HMM 1372 1386	Survival rates
T11	HMM 1472 1475	PRA
T12	HMM 1495 1514	ng·ml⁻¹·h⁻¹
T13	HMM 1531 1537	17.35)
T14	HMM 1624 1640	before treatment
T15	HMM 1661 1680	ng·ml⁻¹·h⁻¹
T16	HMM 1686 1693	(155.18
T17	HMM 1811 1821	days after
T18	HMM 1841 1849	(2.02 ±
T19	HMM 1856 1875	ng·ml⁻¹·h⁻¹
T20	HMM 1928 1951	pg/ml, t = 4.97 - 15.61
T21	HMM 2176 2194	23.15) ml/min, t =
T22	HMM 2395 2404	group vs.
T23	HMM 2405 2407	16
T24	HMM 2541 2570	with chronic severe hepatitis
T25	HMM 2577 2632	decrease PRA, AII and ALD levels significantly increase
T26	HMM 2659 2674	renal damage to
